Low mood during perimenopause can raise an uncomfortable question: is this a hormonal change, depression, or both? The distinction matters because it changes the conversation about treatment. NHS menopause guidance recognises mood symptoms alongside disrupted sleep and concentration. A useful assessment takes those connections seriously whilst leaving room for other explanations. There is no need to choose an explanation before asking for help.
The brain belongs in the menopause conversation
Menopause is often discussed through periods and hot flushes. That leaves a considerable part of the experience outside the frame. The NHS includes low mood, anxiety, memory difficulties, and problems concentrating among the symptoms people may notice. It also explains that sleep disruption can make mood and cognitive symptoms feel worse. These are reasons to describe the whole pattern at an appointment, rather than mentioning only the most visible physical change.
The brain connection is real, but it needs careful language. In a 2021 brain-imaging study in Scientific Reports led by Lisa Mosconi, researchers examined 161 women aged 40–65 and reported differences in brain structure, connectivity, and energy use across menopause stages. Some changes appeared to be temporary. This was research into the transition, not a test that could explain an individual woman’s mood or select her treatment.
Biology can help make an experience intelligible. It should not become another reason to dismiss it. A scan finding and a person’s difficulty getting through the day answer different questions; neither substitutes for a conversation about symptoms, safety, and support.
Low mood and depression need different questions
A difficult week does not establish a diagnosis of depression. Equally, a menopause explanation should not make persistent distress seem inevitable. NHS guidance on depression symptoms describes sustained sadness or hopelessness, loss of interest, and changes that interfere with daily life. It advises seeing a GP when symptoms occur for most of the day, every day, for more than two weeks.
That timeframe is a prompt for assessment, not an instruction to wait when things are severe. Depression can involve irritability, reduced energy, disturbed sleep, and withdrawal from activities. Some of those experiences overlap with menopause symptoms. A symptom list cannot reliably sort them into separate boxes, particularly when several are happening together.
For a consultation, examples may be more useful than a label: whether enjoyment has disappeared, whether work feels unmanageable, or whether contact with friends has become difficult. The aim is to convey duration and impact. The reader does not need to arrive having decided whether the cause is hormonal or psychological.
A hormonal contribution is plausible, not exclusive
NHS guidance on the causes of depression explains that there is no single cause. Menopause can be a trigger, but so can bereavement, relationship difficulties, illness, and money or work worries. Different factors can combine. The guidance also distinguishes sadness and mood swings associated with menopause from depression.
That broader picture matters when deciding what to bring to a consultation. Changes in periods and physical symptoms deserve attention, alongside circumstances that have made life harder. A hormonal transition does not make a bereavement less significant. A difficult period at work does not make menopause symptoms irrelevant. Both can be part of the same account, without the reader having to rank them before speaking to someone.
The NHS also identifies family history, loneliness, and long-term illness among possible contributors. An underactive thyroid can cause depression in some people. These are examples of why an assessment may look beyond menopause. They are not a checklist for self-diagnosis or a reason to request every possible test.
A useful starting point is a description of what changed and what now feels difficult. Choosing a single explanation too early can narrow that description. The aim of the conversation is to leave enough room for the clinician to consider the whole situation.
What is the treatment intended to improve?
NHS menopause treatment guidance describes hormonal and non-hormonal options. HRT is one possibility for menopause symptoms; other treatments remain available when it is unsuitable, unwanted, or does not help. Antidepressants may be offered for low mood, depression, or anxiety related to the transition. The existence of several options makes the treatment goal worth stating clearly.
For example, a discussion might concern physical menopause symptoms, mood symptoms, or both. Those are questions to raise with the clinician, rather than conclusions that follow automatically from being in perimenopause. Before deciding, a reader can ask which symptoms a proposed option is expected to address and how the response will be reviewed.
The same NHS guidance cautions that there is little evidence for the effectiveness or safety of herbal menopause remedies, and some can cause serious side effects when combined with other medicines. A product described as natural therefore still belongs on the medicines list brought to an appointment. It is not an evidence-based substitute for an assessment.
The next step need not be a commitment to one treatment. It can be a clearer discussion of the problem, the available choices, and the information needed to decide.
Guidance allows more than one route to care
NICE’s menopause recommendations, amended in 2024, distinguish depressive symptoms below the threshold for a depression diagnosis from suspected or diagnosed depression. Clinicians may consider HRT when those symptoms began around the same time as other menopause symptoms. CBT is another option for depressive symptoms associated with hot flushes and sweats, including when other choices are unsuitable or unwanted. Suspected or diagnosed depression calls for the depression guideline alongside menopause guidance.
That distinction keeps treatment matched to the problem. NICE’s 2022 depression guideline calls for assessment beyond simply counting symptoms: severity, history, duration, and the course of the illness matter. Options are discussed in relation to clinical needs and preferences. Antidepressants are not routinely the first treatment for less severe depression unless they are the person’s informed preference.
A reasonable discussion therefore includes what the proposed treatment is intended to improve, how progress will be reviewed, and what happens if symptoms persist. The goal is a care plan that can respond to the person, rather than a contest between hormonal and non-hormonal explanations.
HRT suitability still needs individual review
A possible mood benefit does not settle whether HRT is suitable. NHS guidance on continuous combined HRT lists important histories to disclose, including breast or oestrogen-sensitive cancer, unexplained vaginal bleeding, blood clots, and liver disease. Some circumstances make a formulation unsuitable; others require a more detailed discussion. This is not a complete checklist for every form of HRT.
The choice of formulation also depends on whether someone still has periods or has had their womb removed, as NHS menopause treatment guidance explains. A possible benefit cannot bypass that assessment. A prescriber needs the medical history and current medicines before deciding which options, if any, are appropriate.
What this means in practice
- For an appointment, bring brief examples of when mood, sleep, periods, and physical symptoms changed. This can help convey the full pattern rather than assuming a single cause.
- Describe what has become harder in daily life, including lost enjoyment or withdrawal. The NHS identifies these as relevant depression symptoms.
- Ask what each proposed option is intended to treat and how improvement will be reviewed. NICE supports decisions based on needs and preferences.
- Bring a medicines list and relevant medical history to any HRT discussion, particularly cancer, clotting, liver disease, or unexplained bleeding.
- Seek prompt help for worsening distress. In England, urgent mental-health help is available through NHS 111 and its mental-health option, or an urgent GP appointment. If life is at risk or you cannot keep yourself safe, call 999 or go to A&E. These routes follow NHS urgent-help guidance; elsewhere, use local crisis or emergency services.
What we don’t know
The brain-imaging study cannot predict an individual’s mood response or decide who needs HRT. It does not establish that hormone treatment prevents dementia or extends life. Observing differences across menopause stages is a different task from testing a treatment for depression. The distinction is especially relevant here: this was a non-randomised, non-treatment study, and its eligibility criteria excluded major psychiatric disorders.
There is also a practical limit to grouping every experience under “menopause mood”. A person may need menopause symptom care, depression care, or both. Research helps frame those possibilities; an individual assessment is needed to work out what they mean in a particular life.
Mood changes deserve space in the menopause conversation. The most useful question is what support fits the symptoms, their impact, and the person experiencing them.
Photo: Teona Swift on Pexels. Illustrative photograph; the person pictured is not identified as having menopause symptoms or depression.
